Alpha-1 Antitrypsin Deficiency

Order AATD testing in every adult with symptomatic fixed airflow obstruction, whether the working label is COPD or asthma. Clinical appearance alone does not reliably distinguish AATD-related COPD from usual COPD, and failure to test misses a cause that changes family counseling and can alter disease-specific treatment decisions. PubMed+1PubMedThe Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in ...ccjmAlpha-1 antitrypsin deficiency: An underrecognized, treatable cause of COPD | Cleveland Clinic Journal of medicine

Also test patients with unexplained bronchiectasis or unexplained liver disease. These presentations can be the initial clinically recognized manifestation of AATD, particularly when respiratory obstruction is absent or not yet documented. PubMedPubMedThe Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in ...

Once an index case is confirmed, offer testing to first-degree relatives. Family testing is the most efficient detection strategy and identifies individuals who may benefit from smoking avoidance, organ-specific surveillance, and reproductive or genetic counseling. PubMedPubMedThe Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in ...

Measure serum AAT and obtain confirmatory genotype or phenotype testing rather than treating an isolated serum value as a complete diagnosis. Diagnostic approaches include genotyping, isoelectric-focusing phenotype analysis, and sequencing when needed to characterize rare variants. PubMed+2PubMedThe Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in ...PubMedDiagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potentialPubMedAlpha-1 Antitrypsin Deficiency - GeneReviews® - NCBI Bookshelf

Interpret an AAT concentration below 11 micromolar as severe deficiency for augmentation-therapy assessment. The postulated protective threshold is 11 micromolar; PiSZ and PiZZ phenotypes average approximately 8 to 16 micromolar, so genotype and phenotype materially refine interpretation near that threshold. ScienceDirect+2ScienceDirectDistinguishing alpha1-antitrypsin deficiency from asthmaPubMedAlpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline - PMCPubMedManagement of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know

Separate low-circulating-AAT lung disease from polymer-retention liver disease. Severe PiZZ disease predisposes both to loss-of-function lung injury and gain-of-function hepatic injury; this distinction prevents the erroneous use of augmentation as liver-directed therapy. ScienceDirect+2ScienceDirectLongitudinal Evaluation of Individuals With Severe Alpha-1 ...PubMedThe Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in ...PubMedAlpha-1 Antitrypsin Augmentation and the Liver Phenotype of Adults With Alpha-1 Antitrypsin Deficiency (Genotype Pi∗ZZ) - PubMed

For pulmonary staging, obtain spirometry and establish whether emphysema is present; augmentation recommendations are tied to documented AATD-associated lung impairment rather than genotype alone. A chest CT can assess emphysema and has been used to measure lung-density progression in augmentation studies. PubMed+3PubMedManagement of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not knowPubMedDiagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potentialpubs rsnaPredicting Emphysema Progression in the CanCOLD Studypubs rsnaQuantification of Emphysema Progression at CT Using ...

Treat AATD-associated COPD with standard COPD interventions: bronchodilators, inhaled corticosteroids when otherwise indicated, supplemental oxygen, preventive vaccinations, and pulmonary rehabilitation. These measures remain foundational whether or not augmentation is used. ccjm+1ccjmAlpha-1 antitrypsin deficiency: An underrecognized, treatable cause of COPD | Cleveland Clinic Journal of medicinePubMedAlpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline - PMC

Smoking cessation is a prerequisite for a favorable augmentation decision. Current smokers were excluded from randomized augmentation trials, and multiple guidelines do not recommend augmentation in patients who continue to smoke. PubMed+3PubMedAlpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline - PMCPubMedManagement of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not knowPubMedAlpha1-Proteinase Inhibitors for the Treatment of Alpha1-Antitrypsin Deficiency: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines - NCBI BookshelfPubMedAlpha-1 Antitrypsin Deficiency - StatPearls - NCBI Bookshelf

Consider intravenous pooled human AAT augmentation for a nonsmoking or former-smoking patient with documented severe deficiency, established emphysema, and optimized pharmacologic and nonpharmacologic COPD management. Augmentation raises serum and epithelial lining-fluid AAT, restores anti-elastase capacity, and reduces loss of CT-measured lung density over time. PubMed+2PubMedAlpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline - PMCPubMedDiagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potentialPubMedAlpha1-Proteinase Inhibitors for the Treatment of Alpha1-Antitrypsin Deficiency: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines - NCBI Bookshelf

Use the FDA-labeled weekly dose of 60 mg/kg for alpha1-proteinase inhibitor products. Weekly treatment is the labeled regimen referenced by the FDA; do not substitute intermittent dosing without a product-specific rationale. fdafda[PDF] Patient-Focused Drug Development for Alpha-1 Antitrypsin Deficiency

FEV1 thresholds differ across guidelines. COPD Foundation guidance recommends augmentation when FEV1 is 65% predicted or lower and advises a benefit-cost discussion when FEV1 exceeds 65%; GOLD considers patients with FEV1 35% to 60% predicted the most suitable group, while Canadian guidance supports consideration at FEV1 25% to 80% predicted in eligible ex-smokers or nonsmokers. PubMed+1PubMedAlpha1-Proteinase Inhibitors for the Treatment of Alpha1-Antitrypsin Deficiency: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines - NCBI BookshelfPubMedAlpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline - PMC

AATD liver disease results from hepatocellular retention of polymerized abnormal AAT, not from inadequate circulating antiprotease activity. Therefore, intravenous augmentation is not recommended to treat liver disease; clinical guidance reports that liver disease neither improves nor worsens with augmentation used for coexisting pulmonary disease. PubMedPubMedThe Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in ...

In adults with severe-risk genotypes, follow liver biochemistries with aminotransferases, alkaline phosphatase, and bilirubin at least annually. Abnormal tests, clinical evidence of chronic liver disease, or suspected fibrosis should prompt hepatology assessment with noninvasive fibrosis testing such as transient elastography and APRI. PubMed+1PubMedAlpha-1 Antitrypsin Deficiency - StatPearls - NCBI BookshelfPubMedAlpha-1 Antitrypsin Augmentation and the Liver Phenotype of Adults With Alpha-1 Antitrypsin Deficiency (Genotype Pi∗ZZ) - PubMed

Refer patients with severe AATD liver disease for transplant evaluation. Liver transplantation is the definitive treatment and restores circulating AAT levels, unlike augmentation therapy, which replaces plasma antiprotease but does not remove the hepatic source of polymerized protein. PubMed+1PubMedAlpha-1 Antitrypsin Deficiency - GeneReviews® - NCBI BookshelfPubMedThe Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in ...

For AATD-associated panniculitis, use dapsone or doxycycline; if disease is refractory, high-dose intravenous AAT augmentation is indicated in GeneReviews management guidance. This indication is distinct from emphysema-based augmentation selection and should prompt dermatology collaboration when diagnosis is uncertain or ulcerative disease is extensive. PubMedPubMedAlpha-1 Antitrypsin Deficiency - GeneReviews® - NCBI Bookshelf

At diagnosis, document smoking status, pulmonary impairment, emphysema status, liver biochemical testing, and first-degree relatives requiring testing. Management should then be directed to the affected organ system: usual COPD care and selective augmentation for severe deficient emphysema, versus fibrosis staging and transplant planning for clinically significant liver disease. PubMed+3PubMedThe Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in ...PubMedAlpha1-Proteinase Inhibitors for the Treatment of Alpha1-Antitrypsin Deficiency: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines - NCBI BookshelfPubMedAlpha-1 Antitrypsin Deficiency - GeneReviews® - NCBI BookshelfPubMedAlpha-1 Antitrypsin Deficiency - StatPearls - NCBI Bookshelf